La vendita allo scoperto per BioCryst Pharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BioCryst Pharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BioCryst Pharma (NASDAQ:BCRX) Azioni, Report sulle vendite allo scoperto

BioCryst Pharma

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharmaceuticals Inc

<a href="https://www.globenewswire.com/Tracker?data=thMGJcWW8AjTyfCdJD1xEBtP9-UfOazyoISk64JnA5BjVTgverx4tk3EokPzyivmSOugN4h9qO92NeHgMVH1owl-X3tJ-hIrPYB6qZ4UkYU=">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq:&nbsp;BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO&#xAE; (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reductions in hospitalizations, emergency room visits and use of on-demand therapies, after beginning treatment with ORLADEYO. &nbsp;
The study will be presented in a poster at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024 national meeting, which is being held in Las Vegas from October 14-17, 2024.
"Our interrogation of claims data builds upon previously reported findings demonstrating that ORLADEYO not only has a favorable impact on the lives of patients with HAE – but the broader healthcare system, as well. Here, our analysis reveals that significant reductions in healthcare resource utilization are achieved across multiple outcomes – such as reductions in hospitalizations and medical visits, including those related to HAE attacks. Decreases in on-demand treatment were also observed. Taken together, our investigation provides promising real-world evidence which supports ORLADEYO's clinical and financial value as a prophylactic therapy for HAE," said Sandra Christiansen, MD, professor of medicine and director of translational research at the US HAEA Angioedema Center at the University of California, San Diego.
The poster Healthcare Resource Utilization among Patients Initiating Berotralstat for the Long Term Prophylaxis of Hereditary Angioedema in the United States (#D20) detailed findings from a retrospective pre-post study that featured analysis of administrative U.S. claims data of patients with HAE in the United States. The analysis focused on eligible patients enrolled in commercial and public health plans who initiated ORLADEYO between December 2020 and December 2022 who had a baseline of at least six months of continuous health plan enrollment prior to starting ORLADEYO&nbsp;(n=260).
<ul>
<li>Significant reductions in HRU were observed in the overall study population following initiation of ORLADEYO (p&lt;0.05), including in: 
<ul>
<li>All-cause hospitalizations (34 percent reduction) and outpatient or emergency room visits (14 percent reduction).</li>
<li>Angioedema-related hospitalizations (52 percent reduction) and outpatient or emergency room visits (44 percent reduction). &nbsp;</li>
</ul>
</li>
<li>Significant reductions in HAE attack-related HRU were also observed (p&lt;0.05), including in: 
<ul>
<li>HAE attack-related visits (51 percent reduction), driven by significant decreases in hospitalization (60 percent) and outpatient or emergency room visits (50 percent).</li>
<li>Reduction in HAE attack-related visits were observed when stratified by body location of the attack, including in the head and upper airways (48 percent reduction), gastrointestinal system (58 percent reduction) and unspecified locations (52 percent reduction).</li>
<li>Additionally, a decrease in use of on-demand therapies administered by a healthcare professional was observed (39 percent reduction) among patients who previously received on-demand treatment.</li>
</ul>
</li>
</ul>

News

BCRX

BioCryst's ORLADEYO Reduces Hospital Visits and Emergency Care for Hereditary Angioedema Patients, Study Shows

Biotech

Health Care

General

BioCryst Pharmaceuticals Has Enrolled The First Participant In A Phase 1 Trial Evaluating BCX17725 For Netherton Syndrome, A Genetic Disorder Affecting The Skin, Hair, And Immune System; Initial Data Expected By End Of 2025

Government

Contracts

The Us Department Of Health And Human Services Has Awarded BioCryst Pharmaceuticals Up To A $69M Contract For The Procurement Of Up To 95,625 Doses Over A Five-year Period Of Rapivab (Peramivir Injection) For Influenza

BioCryst Pharmaceuticals Has Completed Negotiations With The Pan-Canadian Pharmaceutical Alliance For Orladeyo (Berotralstat), Which Is Approved In Canada For The Routine Prevention Of Attacks Of Hereditary Angioedema For Patients 12 Years Of Age And Older

<a href="https://www.globenewswire.com/Tracker?data=7XUiJbtvdrsn6XxPZLvhx4I22y-w7FTXimBG_O8iw4lOkc10Ojls36Kl3lM2i5K9PWZiuCOFzYW-AR3rKYGVxlDj1CLihCxmk4CrjN3knVye720WpsxZTuGQ6vqru2fbimAvQoqw7Y4tRAi9o9KXJf1ugb6PXVnzfdI7hdFOb0nvo51qlaEHL_jFJ7s20yy8YFW7moeB5w--sUIjrglDrS9axU1AIYk5ywudjhGpunM4knWngdq-Si9LmJVz7U0BYNGjfshIiOZEI1Zp84IZhQ==">BioCryst Pharmaceuticals, Inc.</a>&nbsp;(Nasdaq:&nbsp;BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared decision making (SDM) between healthcare providers (HCPs) and their hereditary angioedema (HAE) patients to provide optimal patient outcomes.
The company is presenting the posters at the 7th Bradykinin Symposium in Berlin from September 5-6, 2024.
<ul>
<li>APeX-N interim results: Oral berotralstat for HAE prophylaxis in Europe</li>
<li>HCP and patient perspectives: HAE long-term prophylaxis and shared decision-making</li>
<li>Adverse health outcomes and perspectives of androgen use in HAE</li>
<li>Evaluation of adherence to berotralstat in patients with hereditary angioedema</li>
<li>Tolerability and effectiveness of berotralstat for long-term prophylaxis in HAE</li>
<li>Effectiveness and safety of berotralstat in HAE with normal C1-inhibitor</li>
</ul>
APeX-N interim results
APeX-N is a European multi-center observational study assessing the safety (primary objective), effectiveness and quality of life (secondary objectives) of berotralstat 150 mg in routine clinical use. This interim analysis included 56 patients from the United Kingdom, France, Germany and Sweden.
Non-serious gastrointestinal adverse events were reported in 12.5 percent of patients. Seven percent (n=4) of patients discontinued treatment (three due to unsatisfactory response, one to participate in a clinical trial). One patient had a severe HAE attack but continued treatment.
"These initial data from APeX-N in Europe reinforce and closely replicate the clinical trial and real-world evidence of berotralstat as the first oral prophylaxis for HAE," said Dr. Sorena Kiani, consultant immunologist at Royal Free London NHS Foundation.
HCP and patient perspectives: HAE long-term prophylaxis and shared decision-making
This study, conducted in Germany, explored the dynamics between HCPs and patients in HAE management, identifying barriers to SDM and strategies to improve it. Ten HCPs participated in 60 minute interviews and simulated patient consultations. Eight HAE patients participated in 30 minute interviews. Participants then convened in structured focus groups to discuss their findings.
The participants identified a need for enhanced HCP awareness of patient perspectives, more comprehensive HCP-patient conversations and improved education about HAE treatment management.
"The findings from this study support the need for further insights to develop future guidance and HAE management strategies to facilitate successful shared decision making and improved patient quality of life," said Dr. Emel Aygören-Pürsün, department for children and adolescents, University Hospital Frankfurt, Germany.

BioCryst Presents Results on HAE Treatment and Patient Care at Global Symposium

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Market Outperform and raises the price target from $15 to $16.

Price Target

Analyst Ratings

JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $16

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Equal-Weight and raises the price target from $6 to $7.

Barclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $7

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Outperform and maintains $10 price target.

Reiteration

RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $10 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $30 price target.

HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target

WIIM

BioCryst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results. Additionally, the company raised its FY24 Orladeyo revenue guidance above estimates.

Earnings

Guidance

BioCryst Pharmaceuticals Says It Expects To Achieve Full-year Operating Profit In 2024, Approach Quarterly Positive EPS And Positive Cash Flow In 2H Of 2025, And Be Profitable On An EPS Basis, With Positive Cash Flow, For Full Year 2026

BioCryst Pharmaceuticals Has Raised Its 2024 Orladeyo Revenue Guidance To $420M-$435M, Up From $390M-$400M

BioCryst Pharma Q2 2024 GAAP EPS $(0.06) Beats $(0.18) Estimate, Sales $109.332M Beat $98.319M Estimate

BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly attack rates after starting oral, once-daily ORLADEYO&reg; (berotralstat). The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain.

Events

BioCryst Announced Data Showing Reductions In Attack Rates In HAE Patients with Normal C1-Inhibitor After Beginning ORLADEYO Treatment

Shares of Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) fell sharply during Wednesday's session after the company reported <a href="https://www.benzinga.com/quote/BOLT/earnings">first-quarter financial results</a>.
Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5.
Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>AERWINS Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWIN#NASDAQ">AWIN</a>) shares surged 201% to $8.16.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) jumped 169% to $0.1449 after jumping over 41% on Tuesday. SINTX Technologies recently posted downbeat quarterly results.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) jumped 87% to $0.5336 after jumping around 368% on Tuesday.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) climbed 53.2% to $6.54 following first-quarter results.</li>
<li>iPower Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) gained 53% to $1.36 after the company reported better-than-expected third-quarter financial results.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) jumped 51% to $0.0850.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares gained 41% to $0.0627 after surging 7% on Tuesday.</li>
<li>Complete Solaria, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) gained 30.6% to $0.90. Complete Solaria signed a term sheet to eliminate Carlyle debt.</li>
<li>OptimizeRx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) jumped 24% to $13.03 following upbeat quarterly results.</li>
<li>Blue Star Foods Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) rose 23% to $0.0686.</li>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) jumped 21.5% to $220.93 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Telos Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) gained 21.4% to $3.85.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) rose 20% to $6.44.</li>
<li>Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) rose 16.5% to $9.47 after the company reported better-than-expected first-quarter financial results.</li>
<li>Dolphin Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) rose 15.4% to $1.2999 after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) jumped 14.3% to $7.98 following first-quarter results.</li>
<li>Nutriband Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) gained 13.5% to $4.34.</li>
<li>Riskified Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) jumped 12.8% to $6.05 following upbeat results.</li>
<li>Cabaletta Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) gained 12.8% to $12.66 following first-quarter results.</li>
<li>Jeffs&#8217; Brands Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) jumped 12% to $0.2530.</li>
<li>B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) rose 11.5% to $9.53.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 11.2% to $0.0529.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) gained 8.1% to $0.0637 after adding around 12% on Tuesday.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) rose 6% to $142.18 after Morgan Stanley maintained an Overweight rating on the stock and raised its price target from $128 to $152.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 63.9% to $0.8199 after the company reported pricing of $2.25m public offering.</li>
<li>Yield10 Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) fell 49.4% to $2.66 after the company reported delisting from the Nasdaq.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) fell 45.8% to $0.4604 after the company announced pricing of $4.7 million public offering.</li>
<li>Pixelworks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) dipped 40.2% to $1.1186 after the company issued soft second-quarter guidance.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares fell 31.9% to $33.22 following a 60% surge on Tuesday.</li>
<li>Koss Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) dipped 31% to $4.24.</li>
<li>VirTra, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) shares fell 30% to $11.49 after the company reported worse-than-expected first-quarter financial results.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) dipped 30.3% to $2.25.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares fell 29.6% to $3.0896. Wolfe Research analyst Steve Fleishman downgraded SunPower from Peer Perform to Underperform.</li>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares declined 28.7% to $1.84 after the company reported downbeat first-quarter sales.</li>
<li>DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) fell 27.5% to $9.84 after the company reported weaker-than-expected first-quarter earnings and said there is a greater likelihood of coming in towards the lower end of its guidance range.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) fell 26.3% to $5.04 after jumping 32% on Tuesday.</li>
<li>Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) declined 25% to $2.7550.</li>
<li>The Oncology Institute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) fell 24.4% to $0.6798 following weak quarterly results.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares fell 23.2% to $4.92 after jumping 442% on Tuesday. The company priced a follow-on offering for gross proceeds of $8.19 million.</li>
<li>Nortech Systems Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) fell 21.1% to $11.97. Nortech Systems is expected to hold a conference call on Thursday, May 16, to discuss the company&#8217;s first quarter financial results.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) fell 16.5% to $1.06.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) declined 12.5% to $11.80.</li>
<li>Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) declined 12.1% to $6.74. Pulse Biosciences named Burke T. Barrett as President and Chief Executive Officer.</li>
<li>iRobot Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) fell 11.8% to $11.24.</li>
<li>BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) fell 10.2% to $3.11.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 9.9% to $4.8000.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) dipped 9.5% to $5.24. New reports indicate the company on Wednesday launched its first vehicle under its new Onvo brand.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) fell 8.7% to $10.22.</li>
<li>Petróleo Brasileiro S.A. &#8211; Petrobras (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) shares fell 8.3% to $15.30. Brazil's President Luiz Inacio Lula da Silva fired Jean Paul Prates, the CEO of Petrobras, following a dispute over dividend.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38844468/jim-cramer-this-industrial-company-is-absolutely-terrific-recommends-buying-modine-manufacturing">Jim Cramer: This Industrial Company Is &#8216;Absolutely Terrific&#8217;, Recommends Buying Modine Manufacturing</a>

Intraday Update

Markets

Movers

AEMD

ARQT

AWIN

BOLT

BSFC

CABA

CDRO

CRKN

CSLR

CTNT

DELL

DLPN

EDBL

FFIE

GWAV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INTZ

IRBT

JFBR

KOSS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MNDY

NOVA

NSYS

NTRB

NVAX

OPRX

PEGY

PLSE

PXLW

RIVN

RSKD

SINT

SLNA

SPCE

SPWR

VRPX

VTSI

YTEN

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Insider Trades

BioCryst Pharmaceuticals Form 4 Filings Shows CCO Charles K Gayer Bought 30,000 Shares At An Average Price Of $5.47/Share; CEO Jon P Stonehouse Bought 30,000 Shares At An Average Price Of $5.55/Share; Steven K Galson Bought 21,940 Shares At An Average Price Of $5.49/Share;  Helen M. Thackray Bought 30,000 Shares At An Average Price Of $5.86/Share; Anthony Doyle Bought 36,300 Shares At An Average Price Of $5.57/Share

U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday.
Shares of Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) rose sharply during Wednesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/NXT/earnings">fourth-quarter financial results</a>.
NEXTracker posted quarterly earnings of 96 cents per share, beating market estimates of 78 cents per share. The company's quarterly sales came in at $736.51 million versus expectations of $683.43 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Nextracker shares gained 7.7% to $46.34 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) gained 21.5% to $220.93 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) surged 20% to $6.44.</li>
<li>Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) gained 16.5% to $9.47 after the company reported better-than-expected first-quarter financial results.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) gained 14.3% to $7.98 following first-quarter results.</li>
<li>Riskified Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) climbed 12.8% to $6.05 following upbeat results.</li>
<li>Cabaletta Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) rose 12.8% to $12.66 following first-quarter results.</li>
<li>B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) gained 11.5% to $9.53.</li>
<li>J.Jill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) rose 9.7% to $31.17. J.Jill said it sees first-quarter preliminary net sales results of about $160 million and adjusted EBITDA of $33 million to $34 million.</li>
<li>Candel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) rose 9.3% to $11.69. Candel Therapeutics posted a first-quarter loss of 28 cents per share on Tuesday.</li>
<li>GoodRx Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) climbed 8.1% to $7.18 after the company announced that it signed a new direct contracting agreement with Kroger.</li>
<li>Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) rose 7.3% to $33.64.</li>
<li>Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) gained 7.1% to $12.36 after the company reported better-than-expected first-quarter sales results. Also, Susquehanna maintained a Positive rating on the stock and raised its price target from $12 to $14.</li>
<li>Shift4 Payments, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) rose 6.8% to $69.46.</li>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) gained 6.2% to $8.60.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) gained 6% to $142.18 after Morgan Stanley maintained an Overweight rating on the stock and raised its price target from $128 to $152.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) rose 5.4% to $50.57.</li>
<li>Vodafone Group Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOD#NASDAQ">VOD</a>) gained 4.2% to $9.58.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38842256/top-3-real-estate-stocks-that-may-implode-in-q2">Top 3 Real Estate Stocks That May Implode In Q2</a>

Trading Ideas

ARVN

CADL

CRML

FOUR

GDRX

JILL

NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday

BioCryst Presents New Real-world Evidence Showing Significant Reductions In Healthcare Resource Utilization Among Patients With Hereditary Angioedema Following Initiation Of Orladeyo (Berotralstat)

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Market Outperform and raises the price target from $14 to $15.

JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $15

The biotech industry is witnessing rapid growth owing to its increasing demand and the inclusion of technological advancements. In this wake, investors could consider adding pocket-friendly biotech stocks Fulcrum Therapeutics (FULC), BioCryst Pharmaceuticals (BCRX), and Precision BioSciences (DTIL) to their portfolio. Continue to read… The biotech industry is currently seeing a heightened demand for high-quality healthcare, innovative treatments, and advanced solutions, largely due to an aging population and escalating healthcare requirements. Given its rapid pace of innovation and promising growth potential, investing in select biotech stocks could be wise.
Amid this backdrop, fundamentally robust biotech stocks such as Fulcrum Therapeutics, Inc. (<a href="https://stocknews.com/stock/FULC/">FULC</a>), BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>), and Precision BioSciences, Inc. (<a href="https://stocknews.com/stock/DTIL/">DTIL</a>) could offer significant return potential owing to their dominance in high-demand areas and transformative treatments.
The biotechnology industry is experiencing rapid growth due to rising demands for personalized medicine, tailored treatments, and the approval of new drugs by the Food and Drug Administration (FDA).
This trend is highlighted in a survey conducted by GlobalData, which reveals that 44% of healthcare industry professionals globally are <a href="https://www.pharmaceutical-technology.com/analyst-comment/biotech-funding-optimism-rises/">optimistic or extremely optimistic</a> about the recovery of biotech funding in the next twelve months.
Incorporating Generative AI (GenAI) into biotechnology subjects is also revolutionizing the industry by enabling companies to derive valuable consumer insights, craft precise marketing strategies, and redefine healthcare engagements.
According to the McKinsey Global Institute, the integration of GenAI is anticipated to contribute an annual economic value of <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/early-adoption-of-generative-ai-in-commercial-life-sciences">$60 billion to $110 billion</a> for pharmaceutical and medtech firms.
Furthermore, according to a report by Precedence Research, the U.S. biotechnology market was valued at $246.18 billion in 2023 and is expected to expand at <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20U.S.%20biotechnology%20market%20size,with%20revenue%20share%20in%202023.">a CAGR of 11.6%</a>, reaching approximately $830.31 trillion by 2034.
Considering these factors, let's discuss the fundamentals of three high-potential <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks under $10, starting with #3.
Stock #3: Fulcrum Therapeutics, Inc. (<a href="https://stocknews.com/stock/FULC/">FULC</a>)
FULC is a clinical-stage biopharmaceutical company focused on treating genetically defined rare diseases. Its clinical product candidates, losmapimod and FTX-6058, are developed for facioscapulohumeral muscular dystrophy (FSHD) and sickle cell disease (SCD), respectively.
On May 13, FULC announced its <a href="https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-enters-collaboration-and-license-agreement">collaboration and license agreement</a> with Sanofi (<a href="https://stocknews.com/stock/SNY/">SNY</a>) for the development and commercialization of losmapimod, for the treatment of FSHD. SNY obtains exclusive commercialization rights for losmapimod outside of the United States under the agreement.
With the help of SNY's global reach, it could become easier for FULC to expand its pipeline and grab a stronger market presence in the FSHD treatment zone.
For the fiscal 2024 second quarter that ended on June 30, 2024, FULC's collaboration revenue increased significantly year-over-year to $80 million. The company's <a href="https://www.investopedia.com/terms/i/ifo.asp">income from operations</a> came in at $52.49 million, compared to a loss of $27.29 million in the previous year's quarter.
Also, its net income and net income per share were reported to be $55.41 million and $0.87, compared to a net loss and net loss per share of $23.78 million and $0.38, respectively.
Analysts expect FULC's revenue to increase 707.3% year-over-year to $7.03 million for the fiscal fourth quarter ending December 2024. Meanwhile, the consensus revenue estimate of $86.56 million for the fiscal year ending December 2024 reflects a significant year-over-year rise.
FULC's stock has gained 30.2% over the past three months and 96.4% over the past nine months to close the last trading session at $9.39.
FULC's bright outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
FULC has a B grade for Value and Quality. It is ranked #26 among 341 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/FULC/">Click here</a> to access FULC's ratings for Growth, Stability, Momentum, and Sentiment.
Stock #2: BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>)
BCRX is a biotechnology company that develops oral small-molecule and protein therapeutics for rare diseases. Its products include ORLADEYO for hereditary angioedema prevention and RAPIVAB for acute uncomplicated influenza treatment in the United States.
On July 9, BCRX announced that its <a href="https://ir.biocryst.com/news-releases/news-release-details/orladeyor-berotralstat-approved-peru">oral, once-daily medication ORLADEYO&#xAE;</a> received approval from the General Directorate of Medicines, Supplies, and Drugs (DIGEMID) in Peru. The approval allows ORLADEYO&#xAE; to be used for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older.
Moreover, the approval in Peru adds to BCRX's established presence in the pan-Latin America region, following previous approvals in Chile, Argentina, Brazil, and Mexico. It signifies a significant milestone for BCRX, expanding its market and potentially attracting more customers seeking treatment for HAE.
BCRX's total revenues increased 32.5% year-over-year to $109.33 million for the fiscal 2024 second quarter that ended June 30, 2024.  Its adjusted income from operations also increased to $21.93 million compared to a loss of $7.86 million in the previous year's quarter.
In addition, as of June 30, 2024, BCRX's cash, cash equivalents and investments amounted to $336.34 million while total assets came in at $472.42 million.
BCRX's consensus revenue estimate of $113.89 million for the fiscal third quarter ending September 2024 reflects a year-over-year increase of 31.3%. Also, for the fiscal fourth quarter ending December 2024, BCRX's revenue is expected to increase by 26% from the prior year to $117.67 million.
In addition, BCRX has topped the consensus revenue estimates in all of the trailing four quarters, which is impressive.
Shares of BCRX have surged 31.3% in the past three months and 45.8% in the past nine months to close the last trading session at $8.05.
BCRX's robust outlook is reflected in its POWR Ratings. The stock has an overall rating of B, translating to Buy in our proprietary rating system.
BCRX has a B grade for Growth, Sentiment, Value, and Quality. It has ranked #17 out of 341 stocks in the Biotech industry.
<a href="https://stocknews.com/stock/BCRX/">Click here</a> to access BCRX's ratings for Stability and Momentum.
Stock #1: Precision BioSciences, Inc. (<a href="https://stocknews.com/stock/DTIL/">DTIL</a>)
DTIL is an innovative gene editing company specializing in developing in vivo therapies for genetic and infectious diseases using its proprietary ARCUS genome editing platform. The company's focus is on advancing gene edits and transformative treatments within these critical medical fields.
On August 9, DTIL announced <a href="https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-investigational-new-drug">U.S. Food and Drug Administration's (FDA) approval</a> for its partner TG Therapeutics, Inc. (<a href="https://stocknews.com/stock/TGTX/">TGTX</a>) to commence Phase I clinical trial of Azercabtagene Zapreleucel (azer-cel) for its Investigational New Drug (IND) Application for progressive forms of multiple sclerosis (MS).
As the company receives approvals for its drugs in the auto-immune disease treatment market, it ensures a stronger market presence and presents better growth prospects.
On July 1, DTIL announced its addition to the <a href="https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-its-addition-russell-microcapr">Russell Microcap&#xAE; Index</a>, a key benchmark utilized by investment managers and institutional investors for index funds. The inclusion could lead to heightened visibility globally, attracting potential investors and fostering further growth opportunities for the company.
<div class="flex-1 overflow-hidden">
<div class="h-full">
<div class="react-scroll-to-bottom--css-ulgnp-79elbk h-full">
<div class="react-scroll-to-bottom--css-ulgnp-1n7m0yu">
<div class="flex flex-col text-sm md:pb-9">
<article class="w-full text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]" dir="auto" data-testid="conversation-turn-17" data-scroll-anchor="true">
<div class="text-base py-[18px] px-3 md:px-4 m-auto md:px-5">
<div class="mx-auto flex flex-1 gap-4 text-base md:gap-5 lg:gap-6 md:max-w-3xl">
<div class="group/conversation-turn relative flex w-full min-w-0 flex-col agent-turn">
<div class="flex-col gap-1 md:gap-3">
<div class="flex max-w-full flex-col flex-grow">
<div class="min-h-[20px] text-message flex w-full flex-col items-end gap-2 break-words [.text-message+&amp;]:mt-5 overflow-x-auto whitespace-normal" dir="auto" data-message-author-role="assistant" data-message-id="8fe0c70b-67a1-4de1-a838-d3c1def07b65">
<div class="flex w-full flex-col gap-1 empty:hidden first:pt-[3px]">
<div class="markdown prose w-full break-words dark:prose-invert dark">
For the fiscal 2024 second quarter that ended June 30, DTIL's revenue increased 152.2% year-over-year to $49.90 million. Its operating income amounted to $24.15 million compared to a loss of $3.13 million in the previous year's quarter.
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</article>
</div>
</div>
</div>
</div>
</div>
Additionally, the company's net income and net income per share came out to be $32.75 million and $4.67 compared to a net loss and loss per share of $11.89 million and $3.13, respectively.
Analysts project DTIL to achieve $57.40 million in revenue for the fiscal year ending December 2024, reflecting a 17.8% year-over-year increase. Additionally, the company is expected to report an EPS of $2.10 for the period. Notably, DTIL has exceeded consensus revenue estimates in three of its last four quarters.
DTIL's shares marginally declined intra-day close the last trading session at $9.85.
The stock's positive fundamentals are reflected in its POWR Ratings. DTIL has an overall rating of B, which equates to a Buy in our proprietary rating system.
DTIL has an A grade for Sentiment and a B grade for Value. It is ranked #16 out of 341 stocks within the same industry.
<a href="https://stocknews.com/stock/DTIL/">Click here</a> to access DTIL's ratings for Stability, Quality, Growth, and Momentum.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt; </a>
&nbsp;

<hr />
BCRX shares were trading at $8.05 per share on Tuesday morning, down $0.18 (-2.19%). Year-to-date, BCRX has gained 34.39%, versus a 18.97% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/bcrx-fulc-dtil-tgtx-sny-3-high-potential-biotech-stocks-under-10/>3 High-Potential Biotech Stocks Under $10</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Potential Biotech Stocks Under $10

BioCryst Pharmaceuticals names Donald Fong as chief medical officer

Tracking Baker Brothers Portfolio - Q2 2024 Update

BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)

BioCryst ( ($BCRX) ) just unveiled an update. BioCryst Pharmaceuticals, Inc. has landed a significant contract with the U.S. Department of Health a...

BioCryst Secures Major US Health Department Influenza Drug Deal

BioCryst Pharmaceuticals awarded $69M influenza treatment contract from U.S. HHS

BioCryst ( ($BCRX) ) has issued an update. BioCryst Pharmaceuticals has commenced a significant Phase 1 trial for BCX17725, a promising KLK5 inhibi...

BioCryst Begins Phase 1 Trial for Netherton Syndrome Treatment

Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on BioCryst (BCRX – Research Report), retaining the price target of $16.00. Jon...

BioCryst's Promising Pipeline and Strategic Growth Potential Underscore Buy Rating

BioCryst Pharmaceuticals ($BCRX), a biotech that creates unique therapeutics for rare conditions, has reported impressive growth metrics and surpas...

Two Key Products Drive BioCryst (BCRX) to New Highs

The biotech industry is flourishing with increasing investments and breakthrough developments. Thus, fundamentally solid small-cap biotech stocks BioCryst Pharmaceuticals (BCRX), Harmony Biosciences (HRMY), and Entrada Therapeutics (TRDA) with potential upside could be worth buying. Read more... The biotech industry is experiencing strong growth and expansion amid increasing investments, robust demand, and a boosting IPO market. Also, the recently announced Fed rate cuts will benefit the market operations.
Amid this backdrop, investors could consider investing in solid small-cap biotech stocks BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>), Harmony Biosciences Holdings, Inc. (<a href="https://stocknews.com/stock/HRMY/">HRMY</a>), and Entrada Therapeutics, Inc. (<a href="https://stocknews.com/stock/TRDA/">TRDA</a>) for significant upside.
The biotech industry continued to rebound in 2024 with pent-up demand, improving technologies, and an optimistic IPO market. September was marked as the <a href="https://www.reuters.com/markets/deals/camp4-therapeutics-seeks-up-283-mln-valuation-us-ipo-2024-10-07/#:~:text=Oct%207%20(Reuters)%20%2D%20Three,after%20a%20two%2Dyear%20slump.">busiest month for healthcare IPOs</a>, encouraged by some strong debuts.
Also, innovative discoveries in areas like oncology, immunology, and neurology supported by increasing investments are bound to propel the biotech industry's prospects. According to <a href="https://investingnews.com/biotech-forecast/#toggle-gdpr">Biopharma Dive</a>, over 12 deals were reported during the second quarter, totaling 28 this year, reflecting strong biotech mergers and acquisitions (M&amp;A) activities.
Besides, <a href="https://www.biopharmadive.com/news/biotech-interest-rates-impact-startups-venture-capital/727479/">the Fed's decision to cut rates</a> for the first time in more than four years will ease the funding environment and also accelerate early-stage drugmakers' operations, and could potentially spur investments in biotech companies.
In addition, the growing R&amp;D initiatives and adoption of digital technologies worldwide would benefit the industry's growth. As per a report by Precedence Research, the <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20global%20biotechnology%20market%20size%20accounted%20for%20USD%201.55%20trillion,USD%20521.02%20billion%20in%202023.">global biotechnology market</a> is expected to reach $4.61 trillion by 2034, growing at a CAGR of 11.5%.
Amid this economic and industry background, small-cap biotech stocks offer great potential for high returns and long-term growth for investors. Small-cap stocks are low-cost and have more growth opportunities.
Therefore, let's delve into the fundamentals of the top three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>)
BCRX is a biotechnology company that develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names, and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
On September 30, BCRX was awarded a $69 million contract by the U.S. Department of Health and Human Services for the procurement of up to 95,625 doses over a five-year period of RAPIVAB&#xAE; (peramivir injection) for treating influenza.
On July 9, BCRX received approval from the General Directorate of Medicines, Supplies, and Drugs (DIGEMID) in Peru for its oral, once-daily ORLADEYO&#xAE; (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.
During the second quarter that ended June 30, 2024, BCRX's total revenues grew 32.5% from the prior year's quarter to $109.33 million. The company's adjusted income from operations was $21.93 million for the quarter.
Furthermore, the company's cash, cash equivalents and, investments and total assets were $336.34 million and $472.42 million as of June 30, 2024.
Analysts expect BCRX's <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> for the third quarter (ended September 2024) to grow 31.3% year-over-year to $113.89 million. Its revenue for the fiscal year 2024 is expected to grow 30.9% year-over-year to $433.84 million. Also, the company topped the consensus revenue estimates in all of the four trailing quarters.
Shares of BCRX have surged 56.2% over the past six months and 17.1% over the past year to close the last trading session at $7.20. Moreover, Wall Street analysts expect the stock to reach $15.33 in the upcoming 12 months, indicating a <a href="https://www.tipranks.com/stocks/bcrx/forecast">potential upside of 116.07%</a>.
BCRX's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
BCRX has a B grade for Quality, Growth, and Value. It is ranked #21 out of 331 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
In addition to the POWR Ratings we've stated above, we also have BCRX ratings for Sentiment, Momentum, and Stability. Get all BCRX ratings <a href="https://stocknews.com/stock/BCRX/">here</a>.
Stock #2: Harmony Biosciences Holdings, Inc. (<a href="https://stocknews.com/stock/HRMY/">HRMY</a>)
HRMY is a commercial-stage pharmaceutical company that focuses on developing and commercializing therapies for patients with rare and other neurological diseases. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action to treat excessive daytime sleepiness in adult patients with narcolepsy.
On June 24, HRMY announced that the U.S. FDA approved its supplemental New Drug Application (sNDA) for WAKIX&#xAE; (pitolisant) tablets treating excessive daytime sleepiness (EDS) in pediatric patients six years of age and older with narcolepsy. With this, WAKIX became the first FDA-approved non-scheduled treatment for pediatric narcolepsy patients.
During the second quarter that ended June 30, 2024, HRMY's net product revenue increased 28.8% year-over-year to $172.81 million. Its gross profit increased 28.8% from the year-ago value to $140.67 million. The company's non-GAAP adjusted net income and EPS came in at $60.61 million and $1.05 per share, up 32.1% and 38.1% from the prior year's quarter, respectively.
Additionally, the company's total assets stood at $858.38 million as of June 30, 2024, compared to $811.45 million as of December 31, 2023.
Street expects HRMY's revenue for the third quarter (ended September 2024) to increase 15.3% year-over-year to $184.81 million, while its EPS is expected to grow 7.2% year-over-year to $0.68, respectively. Furthermore, the company surpassed the consensus revenue estimates in all of the trailing four quarters.
HRMY's stock has gained 16.5% over the past six months and 6.6% over the past year to close the last trading session at $34.75. Wall Street expects the stock to reach $52 in the near term, indicating a <a href="https://www.tipranks.com/stocks/hrmy/forecast">potential upside of 49.38%</a>.
HRMY's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
The stock has an A grade for Value and a B grade for Quality. HRMY is ranked #14 among 331 stocks in the Biotech industry.
<a href="https://stocknews.com/stock/HRMY/">Click here</a> to access HRMY's ratings for Momentum, Growth, Stability, and Sentiment.
Stock #1: Entrada Therapeutics, Inc. (<a href="https://stocknews.com/stock/TRDA/">TRDA</a>)
TRDA is a clinical-stage biotechnology company that develops endosomal escape vehicle therapeutics for treating multiple neuromuscular diseases. The company's EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.
On June 24, TRDA announced positive preliminary data from its Phase 1 clinical trial, ENTR-601-44-101. It reported that ENTR-601-44 was taken well by healthy volunteers with no serious or drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams, or laboratory assessments.
ENTR-601-44 also showed significant plasma concentration, muscle concentration, and exon skipping at levels suggesting potential for a clinically meaningful starting dose in planned upcoming patient trials.
During the second quarter, which ended June 30, 2024, TRDA's collaboration revenue increased 421.1% year-over-year to $94.69 million, and its income from operations was $53.42 million for the same period. The company's net income amounted to $55.03 million or $1.55 per share, against a net loss of $25.93 million and $0.78 per share during the prior year's quarter, respectively.
Street expects TRDA's revenue for the fiscal year (ending December 2024) to increase 36.3% year-over-year to $175.89 million, and its EPS for the same period is expected to be $0.62. Also, the company has surpassed the consensus revenue estimates in each of the trailing four quarters, which is impressive.
TRDA's stock has gained 21.9% over the past six months and 15% over the past year to close the last trading session at $16.39. Also, Wall Street analysts expect the stock to reach $21.50 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/trda/forecast">upside of 32.55%</a>.
TRDA's POWR Ratings reflect its robust outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Value and Quality. It also has a B grade for Sentiment. Within the same industry, TRDA is ranked #13 among 331 stocks.
<a href="https://stocknews.com/stock/TRDA/">Click here</a> to access additional ratings of TRDA for Momentum, Growth, and Stability.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
HRMY shares were unchanged in after-hours trading Wednesday. Year-to-date, HRMY has gained 4.02%, versus a 22.57% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/hrmy-bcrx-trda-3-small-cap-biotech-stocks-to-buy-for-major-upside/>3 Small-Cap Biotech Stocks to Buy for Major Upside</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Small-Cap Biotech Stocks to Buy for Major Upside

ABBV

ABCL

ACAD

AKRO

ARGNF

ARGX

ASPR

BCYC

BEIGF

BGNE

DTIL

EWTX

FULC

HRMY

IMCR

INCY

INSM

KYMR

MDGL

RARE

REPL

ROIV

RVMD

RVMDW

RYTM

TGTX

TRDA

TRXPF

Press Releases

BioCryst to Present at Upcoming Investor Conferences

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Management

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

Comments

BioCryst Pharma

Vendite allo scoperto

BioCryst Pharma (NASDAQ:BCRX) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO